PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
Globe Newswire•15/10/2026•08:30 ET
0
Key Highlights
- ➤October 28 Investor Day to outline PolyPid 2030 growth and pipeline strategy
- ➤D-PLEX₁₀₀ NDA under FDA Priority Review; PDUFA goal date November 28, 2026
- ➤PD01B introduced for diabetic foot infections using Kynatrix™ delivery technology
- ➤SHIELD II showed 60% relative risk reduction in secondary SSI endpoint (p=0.0013)
Expert Statements
Warren S. Joseph, DPM, FIDSA; Key Opinion Leader and specialist in lower extremity infectious diseases
“the clinical burden of diabetic foot infections, the limitations of current treatment approaches, and the potential role of locally delivered, controlled-release antibiotic therapy in this setting”
Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy
Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases
Get started
Create a free account to read the full story.